ALEMBICLTDAlembic Ltd.

₹99.32-1.18%

Market Cap

₹2,577.58 Cr

Stock P/E

8.14

ROCE

6.95%

ROE

6.39%

Book Value

₹91.77

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Alembic Ltd. shows strong revenue growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs industry. The company is positioned well with low debt levels, making it an attractive investment choice. However, some peers display higher profitability and lower valuations, suggesting areas of potential opportunity for investors.

Key Points

• Alembic Ltd. leads in revenue growth YoY (23.77%) and has low debt-equity ratio (0.0042).
• Divi's Laboratories has the highest EPS (82.53) but also has a high PE ratio (73.20), indicating potential overvaluation.
• Dr. Reddy's Laboratories ranks high in profitability metrics with ROE (21.76%) and ROCE (26.86%).
• Cipla Ltd. offers a strong PEG ratio (0.35), indicating good growth potential relative to its valuation.
• Mankind Pharma shows significant revenue growth over 3 years (155.25%), suggesting robust expansion.

Top Performers

Dr. Reddy's Laboratories Ltd.

High profitability with ROE of 21.76% and low PE ratio of 15.50.

Cipla Ltd.

Strong growth and profitability with ROE of 16.63% and attractive PEG ratio of 0.35.

Mankind Pharma Ltd.

Outstanding revenue growth (155.25% over 3 years) with manageable debt levels.